Filing Details

Accession Number:
0001104659-23-089331
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-08-09 16:30:20
Reporting Period:
2023-08-07
Accepted Time:
2023-08-09 16:30:20
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1649904 Rhythm Pharmaceuticals Inc. RYTM Pharmaceutical Preparations (2834) 462159271
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1801372 Kayden Jennifer Lee 222 Berkeley Street, 12Th Floor
Boston MA 02116
Evp, Head Of North America No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-08-07 8,591 $6.80 14,517 No 4 M Direct
Common Stock Disposition 2023-08-07 11,223 $24.18 3,294 No 4 S Direct
Common Stock Acquisiton 2023-08-09 1,718 $6.80 5,012 No 4 M Direct
Common Stock Disposition 2023-08-09 1,718 $24.66 3,294 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2023-08-07 8,591 $0.00 8,591 $6.80
Common Stock Stock Option (Right to Buy) Disposition 2023-08-09 1,718 $0.00 1,718 $6.80
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
73,909 2032-02-08 No 4 M Direct
72,191 2032-02-08 No 4 M Direct
Footnotes
  1. Includes 986 shares acquired under Issuer's Employee Stock Purchase Plan on February 28, 2023.
  2. The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 8, 2023.
  3. The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.